

October 1, 2018

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Sub: Update on intimation regarding the Orthopaedic Business

Reference is made to the intimation made to the Stock exchanges on August 10, 2018 by the Company in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the approval of the Board for the transaction with True North for Orthopaedic and Pain Management Business.

We now wish to inform you that the Company has completed the formalities.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Kuber
Company Secretary & Compliance Officer